{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:17:23Z","timestamp":1785172643232,"version":"3.55.0"},"reference-count":12,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Tildrakizumab (TIL) binds selectively to the p19 subunit of interleukin 23. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti-IL-12\/23 class) and survival. Retrospective analysis of a multicenter, observational study of real clinical practice including patients with moderate-to-severe plaque psoriasis in treatment with TIL. This cross-sectional analysis includes information of patients between February 2019 to February 2022. A total of three tertiary hospitals in Andalusia (Spain) participated in this study. Analyses were performed \u201cas observed\u201d using IBM SPSS v28 for Windows. A total of 61 patients were included in the analysis. The mean age of our patients was 49.5 years; 50.18% of the patients were female and 34.42% of the patients had a BMI greater than 30. It was notable that 44.26% of our patients had scalp involvement. Almost 35% of the patients had psoriatic arthropathy, although skin involvement was predominant. At week 52 (n = 34), 68% of the patients presented an absolute PASI equal to or less than 1. Regarding the drug survival, eight patients discontinued treatment due to inefficacy: five primary and three secondary failures, and one death due to causes not drug related showing survival of 86% at week 52. In the analysis of subgroups of patients, we found that scalp involvement determined greater survival (94%), as well as a shorter duration of the disease (91.7% vs. 84.4% in those with less than 10 years versus more than 15 years of evolution) and with a lower number of previous biological therapies (100% na\u00efve, 90% in those who have used one line of biological therapy and 82.1% in those who have completed two or more lines of biological treatment. Tildrakizumab showed excellent results in the control of psoriasis in the mid-term with an elevated number of patients maintaining treatment after 52 weeks. There were no statistically significant differences in the efficiency, safety or survival results of TIL between patients coming from previous therapies.<\/jats:p>","DOI":"10.3390\/jcm11175098","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:13:56Z","timestamp":1661904836000},"page":"5098","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"first","affiliation":[{"name":"Department of Dermatology, Servicio de Dermatolog\u00eda, Hospital Universitario San Cecilio, Avenida de la Investigaci\u00f3n s\/n, 18016 Granada, Spain"},{"name":"Spain Biohealth Research Institute in Granada (ibs.GRANADA), 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Rodriguez Fernandez-Freire","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Virgen del Rocio, 41013 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0811-9079","authenticated-orcid":false,"given":"Pilar","family":"Font-Ugalde","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario San Reina Sof\u00eda, IMIBIC, 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Galan-Gutierrez","sequence":"additional","affiliation":[{"name":"Hospital Universitario San Reina Sof\u00eda, IMIBIC, 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/24755303221077211","article-title":"Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data","volume":"7","author":"Wei","year":"2022","journal-title":"J. Psoriasis Psoriasis Arthritis"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: Pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_3","first-page":"e355","article-title":"Tildrakizumab: Short-term efficacy and safety in real clinical practice","volume":"61","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_4","first-page":"802","article-title":"Managing Psoriasis Consultations During the COVID-19 Pandemic: Recommendations From the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (AEDV)","volume":"111","author":"Puig","year":"2020","journal-title":"Actas Dermosifiliogr."},{"key":"ref_5","first-page":"2021-2-6","article-title":"Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting","volume":"10","author":"Burlando","year":"2021","journal-title":"Drugs Context"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000519924","article-title":"Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients","volume":"238","author":"Drerup","year":"2022","journal-title":"Dermatology"},{"key":"ref_7","first-page":"e15488","article-title":"Tildrakizumab in moderate-to-severe plaque psoriasis: A multi-center, retrospective, real-life study","volume":"35","author":"Caldarola","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/jdv.15862","article-title":"Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: A pooled analysis of two randomized controlled trials","volume":"33","author":"Blauvelt","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: Pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/09546634.2020.1789051","article-title":"COVID-19 and psoriasis: Biologic treatment and challenges","volume":"33","author":"Ebrahimi","year":"2022","journal-title":"J. Dermatolog. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Gisondi, P., Geat, D., Bellinato, F., and Girolomoni, G. (2022). Use of biologics during the COVID-19 pandemic: Lessons learned from psoriasis. Expert Opin Biol Ther., 1\u20139.","DOI":"10.1080\/14712598.2022.2110467"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"T583","DOI":"10.1016\/j.ad.2022.01.040","article-title":"Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2\u2014Management of Special Populations, Patients With Comorbid Conditions, and Risk","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/17\/5098\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:20:21Z","timestamp":1760142021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/17\/5098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":12,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["jcm11175098"],"URL":"https:\/\/doi.org\/10.3390\/jcm11175098","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]}}}